Following Its Expected Launch Next Year in the U.S. and Europe for Second-Line Treatment of Colorectal Cancer, Regeneron/S

However, Zaltrap’s Market Impact for CRC May Be Even Greater If It Demonstrates Efficacy in the First-Line Setting, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch in 2012 in the United States and Europe for the treatment of colorectal cancer (CRC), Regeneron/Sanofi's Zaltrap (aflibercept) will earn peak-year sales in the second-line setting of up to $250 million in the world’s major pharmaceutical markets. However, if Zaltrap demonstrates efficacy in the first-line setting, its impact on the CRC drug market may be even greater.

Recently released data from the VELOUR clinical trial showed improved overall survival in patients with metastatic CRC who received Zaltrap in combination with FOLFIRI* as compared to patients who received FOLFIRI alone in the second-line setting.

The Pharmacor findings from the topic entitled Colorectal Cancer reveal that emerging anti-vascular endothelial growth factor (VEGF) agents such as Zaltrap and ImClone Systems/Eli Lilly’s ramucirumab will compete with well-established drugs in this space, most notably Genentech/Roche/Chugai’s Avastin (bevacizumab). However, the findings reveal that the impact of Zaltrap and ramucirumab on Avastin sales will only be modest.

“Despite the subtle mechanistic differences of these agents as compared to Avastin and other possible advantages over Avastin, we expect that Zaltrap and ramucirumab will likely have only a minimal impact on Avastin sales as a result of Avastin being the first-to-market anti-VEGF treatment for colorectal cancer,” said Decision Resources Analyst Regina Jammen.

The findings also reveal that AEterna Zentaris/Keryx Biopharmaceuticals/Yakult Honsha’s perifosine represents an entirely new class of drug for CRC treatment. The PI3-K/Akt pathway, which perifosine targets, remains an interesting avenue for therapeutic intervention for cancers.

“If approved, perifosine will likely find applicability in heavily pretreated CRC patients,” Ms. Jammen said.

*FOLFIRI: 5-fluorouracil (5-FU [generics], leucovorin [folinic acid] [generics], irinotecan [Pfizer’s Camptosar/Campo, Daiichi Sankyo’s Topotecin, Yakult Honsha’s Campto, generics])

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Clinical Trials  Oncology  Pharmaceutical  Other Health  Professional Services  Consulting  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.